Tech Center 1600 • Art Units: 1639 1654 1658 1676
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18265523 | SCG2 NEUROPEPTIDES AND USES THEREOF | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 17169835 | SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18105658 | PEPTIDES FOR ANGIOGENIC THERAPY | Final Rejection | The Regents of the University of California |
| 17768537 | Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17296795 | PEPTIDE LIGANDS FOR CAPTURE OF HOST CELL PROTEINS | Non-Final OA | North Carolina State University |
| 17292265 | SELF-ASSEMBLING VEGF NANOPARTICLES | Non-Final OA | Northwestern University |
| 17778306 | POLYPEPTIDE INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY AND USES THEREOF | Final Rejection | The Regents of the University of Michigan |
| 17433009 | CARBAMOYL PHOSPHATE SYNTHATASE-1 FOR THE TREATMENT AND PREVENTION OF LIVER INJURY | Non-Final OA | The Regents of the University of Michigan |
| 17279807 | INJECTABLE COMPOSITION | Non-Final OA | Sumitomo Pharma Co., Ltd. |
| 16632226 | COMPOSITIONS AND METHODS COMPRISING SELF-ASSEMBLING PEPTIDE-POLYMER NANOFIBERS FOR SUBLINGUAL IMMUNIZATION | Final Rejection | Duke University |
| 18037098 | VIBRIO TOXIN BINDING PROTEINS IN SHRIMP AND USES THEREOF | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18872790 | PREVENTING ALU SINES-MEDIATED PATHOLOGIES | Final Rejection | UNIVERSITY OF SOUTH FLORIDA |
| 17408582 | PHOTOACTIVATED CROSSLINKING OF A PROTEIN OR PEPTIDE | Final Rejection | Cook Medical Technologies LLC |
| 18140681 | POLYMERIC CONJUGATES AND USES THEREOF | Final Rejection | Ramot at Tel-Aviv University Ltd. |
| 18265883 | METHODS OF MAKING WATER-SOLUBLE PROTEIN FORMED IN A BACTERIAL EXPRESSION SYSTEM, COMPOSITIONS, AND METHODS OF USE THEREOF | Non-Final OA | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK |
| 18037372 | HYDROXYSTEARIC ACID FOR INDUCING GENERATION OF ANTIMICROBIAL PEPTIDES | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 17396304 | Growth Hormone-Releasing Hormone Antagonists and Uses Thereof | Non-Final OA | University of Miami |
| 17781571 | PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Non-Final OA | ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD. |
| 18439838 | FUNTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | Non-Final OA | IKARIA INC. |
| 18432983 | COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-beta | Non-Final OA | Anchored RSK3 Inhibitors, LLC |
| 18426877 | Treatment of Homologous Recombination Deficient Cancers | Final Rejection | Sinai Health System |
| 18392074 | Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof | Non-Final OA | ORAMED LTD. |
| 18530002 | MODIFIED SERPINS FOR THE TREATMENT OF BRADYKININ-MEDIATED DISEASE | Final Rejection | PRECLINICS GESELLSCHAFT FÜR PRÄKLINISCHE FORSCHUNG MBH |
| 18042001 | HEMOSTATIC ELASTIN-LIKE POLYPEPTIDES | Non-Final OA | UNIVERSITÄT BASEL |
| 17916295 | BROAD-SPECTRUM ANTIVIRAL PEPTIDES | Non-Final OA | The Administrators of the Tulane Educational Fund |
| 18288796 | PREPARATION AND APPLICATION OF POLYPEPTIDE | Non-Final OA | GUANGDONG RAYNOVENT BIOTECH CO., LTD. |
| 18067991 | NITRIC OXIDE HYDROGEL FOR PROMOTING TUMOR VASCULAR NORMALIZATION AND RADIOSENSITIZATION AND PREPARATION METHOD THEREOF | Non-Final OA | Nankai University |
| 17989817 | TARGETING G3BP AGGREGATION TO PREVENT NEURODEGENERATION | Non-Final OA | Tel HaShomer Medical Research Infrastructure and Services Ltd. |
| 17610844 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | Non-Final OA | SENJU PHARMACEUTICAL CO., LTD. |
| 18245226 | A SYSTEM TO IMPROVE HAEMOSTATIC CONTROL | Non-Final OA | Tissue-Link ApS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy